Native Antigen signs distribution agreement with BIOZOL and Shanghai Bioleaf
11th July 2019
The Native Antigen Company, one of the world’s leading suppliers of reagents that enable research into vaccine development and diagnostics for emerging and endemic infectious diseases, announced today that it has appointed BIOZOL and Shanghai Bioleaf to distribute its high-quality products in Germany, Switzerland and Austria, and China, respectively. The appointment of these two distributors will provide researchers in these territories with improved access to The Native Antigen Company’s native and recombinant viral and bacterial antigens, antibodies and immunoassays, supporting cutting-edge research in infectious disease.
The Native Antigen Company specialises in the isolation and purification of native antigens and recombinant proteins from viral and bacterial pathogens in mammalian cell expression systems. Its products have been widely adopted by leading pharmaceutical, in vitro diagnostic (IVD) assay manufacturers, and academic groups in cutting-edge vaccine research and serology, where correct folding and glycosylation are vital.
BIOZOL is one of the leading life-science providers in Germany, Switzerland and Austria, offering over 6,000,000 products from different manufacturers including antibodies, proteins, ELISAs, detection kits, biochemicals, small molecules, reagents for protein analysis, products for human and veterinary diagnostics. Shanghai Bioleaf is a leading biotech company that supplies a wide range of the highest quality research reagents and instruments to meet the growing needs of Chinese professionals in the fields of molecular biology, immunology, cell biology and IVD.
Dr Andy Lane, Commercial Director, The Native Antigen Company, said: “The Native Antigen Company partners with a number of specialist life sciences distributors around the world and we are pleased to be expanding this network across Europe and Asia. BIOZOL and Bioleaf are both well-established distributors who have extensive local knowledge and sales infrastructure in these overseas markets which will allow us to deliver our growing range of reagents to researchers working in academia and industry.”